Scholarlink

<p>Hepatocellular carcinoma (HCC) is a major cause of cancer deaths with few treatment options. Cuproptosis, a copper-dependent cell death pathway, is a promising therapeutic target for HCC. In the present study, cuproptosis-related genes in HCC were identified from GeneCards, with dihydrolipoamide dehydrogenase (DLD) emerging as the top hub gene via STRING and Cytoscape analysis. DLD was markedly overexpressed in HCC tissues compared to normal liver tissues (<i>P</i> = 4.6 × 10⁻⁵) and was associated with advanced TNM stage, fibrosis, and reduced overall survival in both the TCGA (<i>P</i> = 0.039) and ICGC (<i>P</i> = 0.002) cohorts. Multivariate analysis identified DLD as an independent prognostic factor (HR = 2.533). GSEA indicated that elevated DLD expression was linked to enhanced glycolysis/gluconeogenesis, tricarboxylic acid cycle, and pyruvate dehydrogenase complex regulation pathways. In vitro, knockdown of DLD inhibited HCC cell proliferation and increased cell death. Importantly, depletion of DLD heightened susceptibility to cuproptosis, which was further augmented by elesclomol to intensify cell death, decrease FDX1 expression, and deplete ATP levels, but effects that were reversed by tetrathiomolybdate. In conclusion, DLD promotes HCC progression through regulating cuproptosis sensitivity, serving as both a prognostic biomarker and a potential therapeutic target for enhancing cuproptosis-based therapies in HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dihydrolipoamide dehydrogenase promotes hepatocellular carcinoma progression and modulates cuproptosis-dependent cell death

  • 期刊论文

  • 发表日期：

    2026年7月29日

查看全文
  • Mao-feng Zhong,
  • Yu-yu Guo,
  • Yuan Tian,
  • Tian-xiao Zheng,
  • Lu-yuan Zhu,
  • Juan Du,
  • Wan-fu Lin

摘要

Hepatocellular carcinoma (HCC) is a major cause of cancer deaths with few treatment options. Cuproptosis, a copper-dependent cell death pathway, is a promising therapeutic target for HCC. In the present study, cuproptosis-related genes in HCC were identified from GeneCards, with dihydrolipoamide dehydrogenase (DLD) emerging as the top hub gene via STRING and Cytoscape analysis. DLD was markedly overexpressed in HCC tissues compared to normal liver tissues (P = 4.6 × 10⁻⁵) and was associated with advanced TNM stage, fibrosis, and reduced overall survival in both the TCGA (P = 0.039) and ICGC (P = 0.002) cohorts. Multivariate analysis identified DLD as an independent prognostic factor (HR = 2.533). GSEA indicated that elevated DLD expression was linked to enhanced glycolysis/gluconeogenesis, tricarboxylic acid cycle, and pyruvate dehydrogenase complex regulation pathways. In vitro, knockdown of DLD inhibited HCC cell proliferation and increased cell death. Importantly, depletion of DLD heightened susceptibility to cuproptosis, which was further augmented by elesclomol to intensify cell death, decrease FDX1 expression, and deplete ATP levels, but effects that were reversed by tetrathiomolybdate. In conclusion, DLD promotes HCC progression through regulating cuproptosis sensitivity, serving as both a prognostic biomarker and a potential therapeutic target for enhancing cuproptosis-based therapies in HCC.